BRIEF-Ferro Corp launches program to increase manufacturing capacity in Ferro pigments business
* Ferro launches global program to increase manufacturing capacity and optimize production of ultramarine pigments
May 4 Regeneron Pharmaceuticals Inc reported a 37.2 percent increase in first-quarter profit, driven by higher demand for its flagship eye drug Eylea.
The company said net income rose to $248.9 million, or $2.16 per share, in the quarter ended March 31, from $181.4 million, or $1.59 per share, a year earlier.
Total revenue, which also includes collaboration revenue from partners Sanofi SA and Bayer AG, rose nearly 10 percent to $1.32 billion.
U.S. sales of Eylea rose 9 percent in the latest quarter.
Eylea accounted for about 68 percent of the U.S. biotechnology company's total revenue in 2016. (Reporting by Divya Grover in Bengaluru; Editing by Savio D'Souza)
* Extending its non-brokered private placement of units of company, announced on May 17, 2017, for an additional 30 days Source text for Eikon: Further company coverage:
* KB Home, General Mills rise after strong quarterly earnings